Zotatifin And EIF4A Platinum Helix Inhibition In Resistant AdvancedTNBC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Carboplatin
Related studies linked through entity extraction aliases.
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of DS-3939a in Participants With Solid Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
- Status
- RECRUITING
- Phase
- PHASE2
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3